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Background: The 2005 ATS/IDSA guidelines defined healthcare-associated pneumonia (HCAP)
as a novel category of pneumonia in patients with significant healthcare exposure in whom
the risk of drug resistant bacteria may be higher. In this study, we compare clinical outcomes
in patients with HCAP who were treated with guideline-concordant antibiotic regimens with
those who were not.
Methods: Medical records of 100 patients meeting HCAP criteria admitted to an academic
tertiary care hospital between January 2009 and January 2011 were retrospectively reviewed.
Cases were divided into guideline-concordant and guideline-discordant groups based on anti-
biotic therapy. Demographic, microbiological and clinical outcome data were compared for
both groups.
Results: Patients in this cohort had multiple co-morbidities, severe pneumonia (mean PSI score
124.1), and significant mortality (22%). 21 of the 100 cases (21.0%) were culture positive, of
which 11 (53.8%) represented drug-resistant pathogens. No statistically significant differences
for any of the four clinical outcome measures were detected between the guideline-
concordant therapy group and guideline-discordant group. In multivariate regression analysis
controlling for possible confounders, similar results were observed, with the exception that
length of stay was significantly longer (3.99 days, p < 0.001) in the discordant group. Threeired pneumonia; CAP-DRP, community-acquired pneumonia drug-resistant pathogens; GEE, general-
care-associated pneumonia; LOS, length of stay; OR, odds ratio; PSI, pneumonia severity index; TST,
clinical stability.
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Guideline concordant therapy in HCAP 1607or more HCAP criteria (OR 10.89) and wound care (OR 6.32) were characteristics found to be
associated with increased risk for drug-resistant pathogens.
Conclusion: In our cohort, the HCAP model identified a population with significant co-
morbidities and increased risk for drug-resistant pathogens, severe pneumonia, and increased
mortality. However, clinical outcomes were not significantly improved with guideline-
concordant antibiotic therapy.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
In 2005 the American Thoracic Society (ATS) and the
Infectious Disease Society of America (IDSA) released
updated practice guidelines for hospital-acquired (HAP)
and ventilator-associated pneumonia (VAP). In these
guidelines, a new category of disease, healthcare-associ-
ated pneumonia (HCAP), was introduced.1 This new entity
was based upon observations that in community-acquired
pneumonia, drug resistant organisms such as Pseudomonas
aeruginosa and methicillin-resistant Staphylococcus aureus
(MRSA) are more frequently implicated in patients with
frequent healthcare exposure. This new classification
comprises patients hospitalized within the last 90 days,
those receiving chemotherapy, wound care or intravenous
antibiotics, residents of nursing homes or long-term facili-
ties, and patients undergoing hemodialysis. For these
groups, the guidelines recommend a more aggressive
empiric antibiotic regimen than that which is used in
community-acquired pneumonia (CAP). However, recent
studies2,3 have suggested that when taken in composite,
the HCAP criteria have a low predictive value for identi-
fying disease caused by drug resistant pathogens. Further-
more, evidence supporting improved outcomes with the
recommended extended-spectrum antibiotic regimen is
lacking. Here, we compare clinical characteristics and
outcomes in patients who received guideline concordant
antibiotics with those who received discordant therapy in
a single-center retrospective HCAP cohort.
Methods
This study was approved by the institutional review board
of the Mayo Clinic Foundation, IRB number 11-000463. Five
hundred and thirty patients admitted to an academic
tertiary care hospital between January 2009 and January
2011 whose discharge diagnosis included pneumonia were
identified by querying ICD-9 billing code records. All
medical records were manually reviewed. One investigator
refereed questions regarding how to apply predetermined
study definitions. Pneumonia was defined by: 2 or more
clinical signs or symptoms (temperature (C) <36.0 or
>38.0; respiratory rate >20 breaths/min; cough; room air
O2 saturation <90%; sputum production; leukopenia <4000/
mm3 or leukocytosis >10,000/mm3; plus radiographic
evidence of infiltrate or cavitation).3 Using these criteria,
171 cases were excluded because another diagnosis was
more likely than pneumonia. An additional 96 cases were
excluded because they met criteria for hospital-acquired or
post-operative pneumonia.The HCAP criteria found in the 2005 ATS/IDSA guidelines
were then strictly applied to the remaining 263 cases,
including: (1) hospitalization for more than 48 h in the last 90
days, (2) residence in a long-term care facility, (3) atten-
dance at an outpatient hemodialysis clinic within 30 days of
admission, (4) receipt of infusion therapy at an infusion
center within 30 days or (5) receipt of outpatient wound care
during the 30 days preceding admission. One hundred and
sixty threecases (62.0%)were therebyclassifiedasCAP,while
100 cases (38.0%) met criteria for HCAP. Patients were
considered immunosuppressed if any of the following were
present: useof systemiccorticosteroids equivalent to>15mg
prednisone daily for >5 days; cytotoxic chemotherapy;
immunomodulating agents (calcineurin inhibitors, myco-
phenolate mofetil, cyclophosphamide, methotrexate, TNF
inhibitors); presence of hypogammaglobulinemia or other
heritable immunodeficiency; active hematologic malig-
nancy; neutropenia (absoluteneutrophil count<1000/mm3);
or HIV/AIDS with a CD4 count <200/mm3. Microbiological
data were included from the following sources: cultures of
sputum, bronchoalveolar lavage fluid, and blood if the
pathogen was consistent with a respiratory source; urinary
antigen tests for Legionella pneumophila and Streptococcus
pneumoniae; respiratory viral panel; and serology in the case
of suspected pulmonary coccidioidomycosis. Bacteria were
classified as community-acquired pneumonia drug-resistant
pathogens (CAP-DRP) if susceptibility testing demonstrated
resistance to antibiotics recommended for CAP, i.e. third-
generation cephalosporins and macrolides. Examples of
CAP-DRP include MRSA, P. aeruginosa, Enterobacteriaceae
expressing extended-spectrum beta-lactamases, and other
resistant non-fermenting gram-negative organisms, such as
Acinetobacter spp. and Stenotrophomonas spp.
The HCAP study group was divided based on antibiotic
treatment. The guideline-concordant group was defined as
patients whose cumulative antibiotic regimen, initiated
within the first eight hours of admission and continued for
at least 48 h, met or exceeded coverage recommended by
2005 ATS/IDSA guidelines: Anti-pseudomonal beta-lactam
plus either a fluoroquinolone or an aminoglycoside, plus
anti-MRSA coverage if risk factors were present. Risk
factors for MRSA in this study included known prior MRSA
infection or colonization, positive nasal MRSA swab prior to
antibiotic decision making, or recent history of intravenous
drug use or incarceration.
Outcomes measured included time to clinical stability
(TCS), time to switch therapy (TST), length of stay (LOS)
and 30-day mortality. TCS was defined as: temperature
<37.2 C, heart rate <100 beats/min, systolic blood pres-
sure >90 mmHg, respiratory rate <24 breaths/min, and
oxygen saturation >90% on room air or return to preexisting
1608 B.J. Webb et al.stable level of oxygen requirement.4 Patients were recor-
ded as non-responders (NR) if they expired, were transi-
tioned to palliative management, or were discharged or
transferred prior to fulfilling criteria for clinical stability.
TST was defined as the number of hours from admission
until either the first dose of an oral-only antibiotic regimen
or monotherapy after de-escalation. Cases were recorded
as “no-switch” if no de-escalation to monotherapy or oral
antibiotics occurred, if they were discharged or transferred
to continue antibiotic therapy, or if antibiotics were dis-
continued due to palliative management or death. LOS was
recorded in half-day increments, and 30-day mortality was
determined using our institution’s notice of expiration
system; the status of all patients in the cohort was verified
at 30 days.
Statistical analysis
Univariate analysis of categorical variables was per-
formed using c2 or Fisher’s exact test, and continuous
variables were analyzed using the unpaired t-test. A
p-value of <0.05 was considered significant and all anal-
yses were two-tailed. It was determined a priori that
multivariate analysis would be necessary to avoidTable 1 Demographic data.
All cases
n Z 100
Demographics
Age (years) 71.3
Gender
Male 48 (48.0)
Female 52 (52.0)
HCAP criteria
Hospitalization 66 (66.0)
Long-term facility 19 (19.0)
Dialysis 4 (4.0)
Infusion 37 (37.0)
Wound care 5 (5.0)
2 or more criteria 29 (29.0)
PSIa 124.1
Number of co-morbidities 3.2
Renal insufficiency 38 (38.0)
COPD/fibrosis 18 (18.0)
CHF 30 (30.0)
Immunosuppression 57 (57.0)
Delirium/dementia 21 (21.0)
Diabetes/hyperglycemia 18 (18.0)
Hepatic disease 7 (7.0)
Neurologic disease 12 (12.0)
Aspiration 15 (15.0)
Malnutrition 1 (1.0)
Malignancy 48 (48.0)
Sepsis 55 (55.0)
Positive pressure/intubation 12 (12.0)
C. difficile 3 (3.0)
Drug-resistant pathogens 11 (11.0%)
Percent (%).
a PSI e Pneumonia Severity Index.incorrect assumptions influenced by confounding vari-
ables. Using a logistical regression model, the data were
then controlled for demographic variables differing at the
p < 0.2 level. The generalized estimate equation (GEE)
with normal link for continuous variables and logit link for
categorical variables was employed in this model because
some patients had more than one admission in the cohort.
A second logistical regression model was constructed in
the same manner in order to investigate factors associ-
ated with disease caused by CAP-DRP. JMP (SAS Institute
Inc., North Carolina, U.S.A. 2011) software was used to
perform statistical analysis.Results
Our study population was characterized by advanced age
and multiple co-morbid conditions, including a high inci-
dence of malignancy (see Table 1). Mean severity of disease
was also high, approaching Pneumonia Severity Index (PSI)
stage V disease.5 Overall mortality at 30 days was 22% in our
cohort. Among HCAP criteria, prior hospitalization (66%)
and intravenous infusion therapy (39%) were most common,
and nearly one-third (29%) of patients met more than oneConcordant
n Z 43
Discordant
n Z 57
p-value
68.7 73.3 0.14
22 (51.2) 26 (45.6) 0.69
21 (48.8) 31 (54.4)
27 (62.8) 39 (69.4) 0.67
8 (18.6) 11 (19.3) 1.0
1 (2.3) 3 (5.3) 0.63
18 (41.9) 19 (33.3) 0.41
2 (4.6) 3 (5.3) 1.0
12 (27.9) 17 (29.8) 1.0
123.4 124.7 0.86
3.33 3.11 0.45
17 (39.5) 21 (36.8) 0.84
7 (16.3) 11 (19.3) 0.80
12 (27.9) 18 (31.6) 0.83
29 (67.4) 28 (49.1) 0.10
7 (16.3) 14 (24.6) 0.34
6 (14.0) 12 (21.1) 0.44
2 (4.6) 5 (8.8) 0.70
5 (11.6) 7 (12.3) 1.0
6 (14.0) 9 (15.8) 1.0
0 (0.0) 1 (1.8) 1.0
25 (58.1) 23 (40.4) 0.11
27 (62.8) 28 (49.1) 0.22
5 (11.6) 7 (12.3) 1.0
1 (2.3) 2 (3.5) 1.0
6 (14.0) 5 (8.8) 1.0
Table 4 Factors associated with CAP-DRP.
Risk factor Odds ratio 95% CI (odds ratio) p-value
3 HCAP risk
factors
10.89 1.36e86.77 0.048
Wound care 6.32 0.93e42.94 0.059
Table 2 Microbiological data.
Organism N (%)
All cases with positive bacterial cultures 21
Drug resistant pathogens (CAP-DRP) 11 (53.8)
Methicillin-resistant Staphylococcus
aureus (MRSA)
4 (19.0)
Pseudomonas aeruginosa 4 (19.0)
Escherichia coli, Extended-Spectrum
b-Lactamase (ESBL) positive
2 (9.5)
Klebsiella pneumoniae, ESBL (þ) 1 (4.8)
Drug sensitive organisms 10 (47.6)
Methicillin-sensitive S. aureus (MSSA) 6 (28.6)
Escherichia coli 2 (9.5)
Serratia marcescens 1 (4.8)
Coagulase-negative Staphylococcus sp. 1 (4.8)
Other organisms 2
Parainfluenza virusa 1
Coccidiodes sp.b 1
a Positive viral culture by shell vial method.
b Positive IgM by enzyme-linked immunoassay.
Guideline concordant therapy in HCAP 1609criterion. Twenty-one patients (21%) had at least one
positive blood (n Z 9) or respiratory culture (n Z 14). Of
the 21 cases with positive cultures, 11 (53.8%) represented
CAP-DRP (Table 2).
Forty-three (43%) patients received antibiotic therapy in
concordance with the 2005 ATS/IDSA guidelines. Demo-
graphic and clinical characteristics were similar between
the concordant and discordant study groups; only immu-
nosuppression and malignancy rates were significantly
different between the two groups and were controlled for
in multivariate analysis. In univariate analysis, no statisti-
cally significant differences in time to clinical stability,Table 3 Statistical analysis.
Univariate analysis: clinical outcomes by guideline concordance
All cases
n Z 100
Concordant
n Z 43
Outcome
TCSa (h) 58.4 53.69
No response (%) 23 (23.0) 11 (25.6)
TSTb (h) 97.9 106.28
No switch (%) 22 (22.0) 7 (16.3)
LOSc (days) 5.33 5.29
30-day mortality (%) 22 (22.0) 9 (20.9)
Multivariate analysis: clinical outcomes adjusted for malignancy
antibiotic therapy
Outcome Estimate Odds
TCS (h) 16.79
TST (h) 4.73
LOS (days) 3.99
Mortality (30 day) 1.56
a TCS e Time to Clinical Stability.
b TST e Time to Switch Therapy.
c LOS e Length of Stay.time to switch therapy, length of stay, or 30-day mortality
were detected between those treated with a guideline
concordant or discordant regimen (Table 3). In a multivar-
iate logistical regression model, a 16.8 h difference in TCS
favoring the concordant group was detected, but this was
not statistically significant, nor was the small difference
noted for TST (see Table 3). In this model however, patients
in the discordant treatment group had a significantly longer
LOS. No significant difference was noted in 30-day
mortality.
In the logistical regression model designed to explore
possible risk factors for disease caused by CAP-DRP, the
presence of three or more HCAP criteria (OR 10.89) and
wound care (OR 6.32) demonstrated significant association,
albeit with wide confidence intervals (Table 4).Discussion
This single center study adds to a growing body of data eval-
uating the HCAP model. Previously published studies have
focused on three general objectives: (1) comparing clinical
characteristics of the population defined by HCAP criteria
with that of CAP,6e13 (2) identifying risk factors for acquiring
pneumonia caused by drug-resistant bacteria,2,7,9,12e16 and
(3) investigatingoutcomes inpatients treatedwith thebroad-
spectrum antibiotic regimen called for by the ATS/IDSA
guidelines.7e10,12e15,17,18Discordant
n Z 57
Odds ratio 95% CI p-value
61.76 0.56
12 (21.1) 1.29 0.50e3.28 0.64
90.73 0.35
15 (26.3) 0.54 0.20e1.48 0.33
5.36 0.93
13 (22.8) 0.90 0.34e2.34 1.0
and immunosuppression Guideline concordant vs. discordant
ratio 95% CI p-value
46.02e12.44 0.26
29.84e39.31 0.79
3.98e4.00 <0.001
0.43e5.55 0.5
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centers indicating that the HCAP model is clearly effective
in identifying a population with significant co-morbid-
ities,6e9,12 severe disease,6e9,11e13 and increased mortality.
For example, in our cohort we noted a 22% mortality rate.
Mortality rates from 13 other HCAP studies, range from 6 to
28%6e15,17,19,20 with a compiled mean of 14%. By compar-
ison, mortality rates from two large CAP databases range
from 4.7 to 8.3%.21,22
The fundamental question regarding the HCAP model is
whether poor outcomes in HCAP patients correlate more
closely with a high prevalence of drug resistant organisms
not targeted by CAP antibiotic regimens, or with other host
factors that have yet to be elucidated. Although multiple
HCAP studies have reported a high prevalence of CAP-DRP,
reported rates vary widely.6,9e12,20,23 In 12 cohorts report-
ing only cases with positive cultures,2,6e12,14,16,17,20 the
prevalence of CAP-DRP ranged from 10.2%8 to 88.0%17 with
a mean of 50.4%. In contrast, in six studies that also
included cases with negative cultures,6e9,12,16 the mean
prevalence was 8.8% (4.1%8e14.4%7). Data from our cohort
align closely to these average figures, with 53.8% of
recovered organisms and 11% of all cases demonstrating
drug-resistance.
Although diversity in regional antimicrobial prescribing
patterns and trends in microbial drug resistance likely
account for much of the variation observed in the preva-
lence of CAP-DRP, other factors may also be contributory.
For example, a standard definition of HCAP has not been
applied consistently throughout the literature. This is likely
due to ongoing questions regarding which patient charac-
teristics convey risk for CAP-DRP. Studies attempting to
clarify these risk factors suggest that the five original
criteria comprising the HCAP model portend varying risk for
CAP-DRP depending on the study population, and may
exclude several important risk factors, such as prior anti-
biotic use, immunosuppression or enteral feeding (see
Table 5). While the significance of prior hospitalization or
long term care has been identified with some regularity, our
study is the first to show that wound care may indeed
convey a risk for DRP. Persistent wounds may be colonizedTable 5 Risk factors for CAP-DRP by publication.
Risk factor # of studies reporting
association
Prior antibiotics2,12,14,16 4
Hospitalization3,9,13,14 4
Long term care2,3,14,16 4
Multiple HCAP risk
factors2,15 (This study)
3
Chronic lung disease2,7,16 3
Tube feeding9,12 2
Immunosuppression2,14 2
Hemodialysis3,14 2
WoundWebb et al. 1
Infusion16 1
Poor functional status12 1
Aspiration risk7 1
Diabetes16 1with drug-resistant pathogens because of the need for
ongoing wound care at medical facilities and empiric anti-
microbial therapy. In addition, our data also support the
observation that cumulative risk for CAP-DRP increases with
multiple HCAP risk factors.2,15
An important corollary to the microbiological validity of
the HCAP model is whether empiric treatment with anti-
biotics targeting CAP-DRP improves outcomes in these
patients. Multiple culture-positive cohorts have reported
increased mortality with inappropriate initial antibiotic
therapy10,12e14,17 However, these results are difficult to
apply in a real-life clinical context in which many cases of
pneumonia remain culture negative. In our cohort,
guideline-concordant antibiotic therapy was not associated
with significant differences in time to clinical stability, time
to antibiotic de-escalation, length of stay, or mortality at
30 days. When the data was adjusted for possible
confounders, similar results were observed with the
exception that LOS was significantly longer in patients
treated with a guideline-discordant regimen.
There are several possible reasons to explain why
guideline-concordant therapy failed to significantly
improve clinical outcomes. First, the positive predictive
value of the HCAP model for CAP-DRP may be insufficient
when applied to all cases, both culture-positive and
negative, such as occurs in the clinical setting. For
example, in our cohort, although CAP-DRP were implicated
in more than half of culture-positive cases, these organ-
isms were implicated in only 11%, or 1 in every 9 cases
overall. Of the 78% of cases that remained culture-
negative, it is possible that very few were due to CAP-
DRP, and therefore may not have benefitted from
extended-spectrum antibiotic therapy. This hypothesis is
supported by two observations from the HCAP literature.
Labelle et al., have demonstrated that culture-negative
HCAP is associated with lower severity and better
outcomes,24 whereas CAP-DRP have been associated with
more severe disease12 and may have a higher probability of
recovery in culture due to enhanced virulence and/or
a larger pathogen burden.
Another possible explanation is that the lack of
improved outcomes may be more closely related to guide-
line definitions of antibiotic regimens than to the predictive
strength of the HCAP model. In some cases, an antibiotic
regimen that was classified as discordant by strict appli-
cation of the guideline definition may have in fact been
microbiologically appropriate. For example, in our cohort,
the most common cause of guideline discordance was
treatment with a single anti-pseudomonal antibiotic. Most
often however, levofloxacin was the agent used, to which
77% of strains of P. aeruginosa at our institution are
susceptible. This suggests that at least some cases in the
discordant group may have in fact received appropriate
initial antibiotic therapy. Although it is not clear why length
of stay was increased in the discordant group in multivar-
iate analysis, it may be due to other clinical confounders
not identified in our study.
Our study was designed to minimize several potential
methodological shortcomings. First, every case was manu-
ally reviewed to avoid the inaccuracies of enrollment based
on billing codes or database queries. In addition, all cases
(both culture-negative and culture-positive) were included
Guideline concordant therapy in HCAP 1611in order to more accurately reflect the clinical context in
which clinicians must make antibiotic choices. Secondly,
we strictly applied the HCAP criteria and antibiotic treat-
ment options described in the 2005 ATS/IDSA guidelines so
that results may be clearly interpreted. Despite these
measures, however, our study had several limitations.
Because of the retrospective design, results from our
cohort are prone to selection bias. We attempted to miti-
gate this by selecting study variables and anticipating the
need to control for possible confounders a priori. Second,
our sample size lacked sufficient statistical power to detect
small differences in outcomes. Lastly, our single center
experience may not necessarily mirror the antibiotic resis-
tance patterns expected from larger multicenter trials.
However, other recent HCAP cohorts have reported
similar results,7,8,15,18 suggesting that the effect of the
above-mentioned limitations on our data may have been
minimal.
Conclusion
In the context of other recent HCAP studies, our findings
suggest that although the HCAP model identifies a pop-
ulation with increased risk for CAP-DRP, this risk appears to
vary with local microbiologic patterns resulting in a low
predictive-value for the model. Perhaps more importantly,
outcome data does not appear to justify the continued use
of extended-spectrum antibiotic therapy in all patients
meeting HCAP criteria. A guideline-concordant regimen
reliably covers most pathogens, but results in over-
treatment in many cases, whereas guideline-discordant
antibiotic choices do not always result in inappropriate
microbiological treatment.
In patients with severe pneumonia in whom the clinical
margin for error is low, initial empiric broad-spectrum
antibiotic therapy targeting CAP-DRP remains a prudent
option, followed by antibiotic de-escalation. While several
authors have developed risk-based treatment algorithms or
clinical scoring models to predict the risk of CAP-DRP-
associated disease, none of these has yet to be widely
validated.2,3,14,16,25 A prospective, multi-center study to
validate a clinical prediction tool for pneumonia caused by
CAP-DRP is needed in order to more accurately guide
empiric antibiotic choice in patients with significant
healthcare exposure.
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